Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Mangalam Drugs & Organics's Equity-to-Asset or its related term are showing as below:
NSE:MANGALAM'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33 Med: 0.43 Max: 0.5
Current: 0.33
During the past 13 years, the highest Equity to Asset Ratio of Mangalam Drugs & Organics was 0.50. The lowest was 0.33. And the median was 0.43.
NSE:MANGALAM's Equity-to-Asset is ranked worse than 80.93% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs NSE:MANGALAM: 0.33
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Mangalam Drugs & Organics Equity-to-Asset Related Terms
Mangalam Drugs & Organics Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Mangalam Drugs & Organics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mangalam Drugs & Organics Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mangalam Drugs & Organics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Mangalam Drugs & Organics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Mangalam Drugs & Organics's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mangalam Drugs & Organics (NSE:MANGALAM) has a Equity-to-Asset of 0.00 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Mangalam Drugs & Organics and its competitors. Over the past decade, Mangalam Drugs & Organics' Equity-to-Asset has ranged from 0.33 to 0.50. According to the industry distribution chart, Mangalam Drugs & Organics ranks #815 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 80.9%.
Is Mangalam Drugs & Organics' Equity-to-Asset too high?
Mangalam Drugs & Organics' current Equity-to-Asset is 0.00. Over the past 10 years, this metric has ranged from a low of 0.33 to a high of 0.50. Based on the distribution chart, Mangalam Drugs & Organics ranks #815 out of 1007 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Mangalam Drugs & Organics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mangalam Drugs & Organics' Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Mangalam Drugs & Organics ranks #815 out of 1007 companies for Equity-to-Asset. This places Mangalam Drugs & Organics in the lower half of its industry. The industry median Equity-to-Asset is 0.60. Historically, Mangalam Drugs & Organics' own Equity-to-Asset has ranged from 0.33 to 0.50 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Mangalam Drugs & Organics and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mangalam Drugs & Organics's current Equity-to-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mangalam Drugs & Organics stock overvalued right now?
Based on GuruFocus' analysis, Mangalam Drugs & Organics (NSE:MANGALAM) is currently considered Possible Value Trap. The stock's GF Value™ is ₹63.10, compared to a current price of ₹30.33 — trading 51.9% below its estimated fair value. The current Equity-to-Asset is 0.00. Mangalam Drugs & Organics' overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Mangalam Drugs & Organics (NSE:MANGALAM), the current Equity-to-Asset is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mangalam Drugs & Organics (NSE:MANGALAM) Overvalued in 2026?
Based on GuruFocus' analysis, Mangalam Drugs & Organics stock appears to be undervalued.
The current stock price of ₹30.33 is trading 51.9% below its estimated GF Value™ of ₹63.10.
GuruFocus considers Mangalam Drugs & Organics to be Possible Value Trap.
Key valuation signals for NSE:MANGALAM:
Equity-to-Asset: 0.00
GF Value™: ₹63.10 vs. price of ₹30.33 (51.9% below fair value)
No single metric tells the full story. See the NSE:MANGALAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mangalam Drugs & Organics Ltd commenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company is engaged in the manufacture and sale of APIs for various therapeutic segments, including anti-malaria, anti-retroviral, and anti-hypertensive. It is approved by the Bill Clinton Foundation. The company is actively producing Pyronaridine Tetraphosphate, a new API used in antimalarial treatments. The company has received prequalification from the World Health Organization (WHO) for both micronized and non-micronized forms of Pyronaridine Phosphate.
44GF Score
Get the complete analysis for NSE:MANGALAM
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MANGALAM has been successfully added to your 
